Eli Lilly Investment Consulting (Shanghai) Co., - 礼来亚洲风险投资基金

Eli Lilly Investment Consulting (Shanghai) Co., Ltd. is a venture capital arm specializes in investments in growth stage and various stages of development from start-up to commercialization. It primarily invests in life science, healthcare, medicine, technology, media, telecommunications and digital innovation sectors. It typically invests in human therapeutics with a focus on biopharmaceuticals, biotechnology, biomedicine, and medical treatment equipment; medical technology with a focus on devices and diagnostics; healthcare services with a focus on hospitals, clinics; animal health; and broader life sciences including industrial biotechnology, agricultural biotechnology, and nutraceuticals. It prefers to invest in companies based in Asia with a focus on China. It seeks to invest between $5 million and $15 million per round. The firm also seeks a board seat or observation rights in its portfolio companies. It only takes a minority stake in a company, usually less than 20 percent. Eli Lilly Investment Consulting (Shanghai) Co., Ltd. was founded in 2008 and is based Shanghai, China, with additional offices in Hong Kong and California, U.S.A.